Prenatal hypocalvaria after prolonged intrauterine exposure to angiotensin II receptor antagonists.
Marine LallemantSarah PrévostFrançois NobiliDidier RiethmullerRajeev RamanahMarie-France SerondeNicolas MottetPublished in: Journal of the renin-angiotensin-aldosterone system : JRAAS (2019)
We report a case of prenatal exposure to angiotensin II receptor antagonists (ARA II) from the beginning of pregnancy in a patient with a hypokinetic dilated cardiomyopathy. This case report emphasizes the fetal renal impact of prolonged intrauterine exposure to renin-angiotensin system (RAS) blockers, and highlights that this exposure can cause severe prenatal hypocalvaria. This delayed ossification can be reversible after birth, but the presence of anhydramnios indicates an early and irreversible block of RAS blockers in the fetus that is responsible for fetal kidney development abnormalities. This association carries a high risk of neonatal death. Prolonged exposure to ARA II or other RAS blockers remains prohibited throughout pregnancy.